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Addiction, neuroplasticity and miRNAs
Drug addiction is a major public health issue. Drugs of 
abuse  modulate  gene  expression,  and  produce  their 
rewarding  effects  of  euphoria  or  pleasure  through  an 
interaction  with  the  mesolimbic  dopaminergic  system, 
leading to persistent alterations (neuroplastic, structural 
and  functional)  in  the  reward-related  and  memory-
related  brain  centers.  An  overview  of  the  pathways 
involved  in  miRNA  regulation  of  gene  expression  in 
addiction  is  shown  in  Figure  1.  Long-term  intake  of 
addictive substances such as cocaine, heroin and nicotine, 
for  example,  results  in  neurological  adaptations  that 
decrease the sensitivity of an individual to these drugs. 
Drugs  induce  persistent  perturbation  of  activity-
dependent synaptic plasticity, progressing towards high-
risk,  drug-seeking  behavior  and  relapse  [1],  but  the 
molecular  mechanisms  leading  to  addiction  are  poorly 
understood.  Emerging  evidence  suggests  that  drug-
induced neuroplasticity depends on epigenetic changes 
in  gene  expression  and  post-transcriptional  regulation 
[2,3], because addiction is typically a multigenetic brain 
disorder,  implying  combined  changes  of  expression  of 
several  hundreds  of  genes.  Tight  regulation  of  such  a 
large array of genes in a very complex behavioral paradox 
is  mediated  by  a  variety  of  transcriptional  and  post-
transcriptional  events  that  control  the  expression  of 
individual gene products. Recently, a novel class of highly 
potent post-transcriptional regulators of gene expression 
has  been  described  that  consist  of  small  (19-25 
nucleotides)  non-coding  RNAs.  These  miRNAs  are 
considered to be ‘master regulators’ of gene expression, 
and  they  control  the  translation  of  target  mRNAs, 
thereby regulating critical aspects of neuroplasticity and 
synapse  consolidation.  In  the  mammalian  nervous 
system, the spatiotemporal control of mRNA translation 
has  an  important  role  in  synaptic  development  and 
plasticity. Targeted mRNAs are selectively and reversibly 
suppressed translationally or subjected to degradation by 
miRNAs, possibly in a combinatorial fashion based on 
the  complementarity  in  the  3’-untranslated  region 
(3’UTR)  of  the  mRNAs.  Local  translational  control  in 
dendritic  spines  is  a  powerful  mechanism  to  regulate 
morphologic  and  functional  plasticity  [2],  and  recent 
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Drug addiction is a major public health issue. It is 
typically a multigenetic brain disorder, implying 
combined changes of expression of several hundred 
genes. Psychostimulants (such as cocaine, heroin 
and amphetamines) induce strong and persistent 
neuroadaptive changes through a surfeit of gene 
regulatory mechanisms leading to addiction. Activity-
dependent synaptic plasticity of the mesolimbic 
dopaminergic system, known as the ‘reward pathway’, 
plays a crucial role in the development of drug 
dependence. miRNAs are small non-coding RNAs, 
particularly abundant in the nervous system, that play 
key roles as regulatory molecules in processes such 
as neurogenesis, synapse development and plasticity 
in the brain. They also act as key spatiotemporal 
regulators during dendritic morphogenesis, controlling 
the expression of hundreds of genes involved in 
neuroplasticity and in the function of synapses. Recent 
studies have identified changes of several specific 
miRNA expression profiles and polymorphisms 
affecting the interactions between miRNAs and their 
targets in various brain disorders, including addiction: 
miR-16 causes adaptive changes in production of 
the serotonin transporter; miR-133b is specifically 
expressed in midbrain dopaminergic neurons, and 
regulates the production of tyrosine hydroxylase and 
the dopamine transporter; miR-212 affects production 
of striatal brain-derived neurotrophic factor and 
synaptic plasticity upon cocaine. Clearly, specific 
miRNAs have emerged as key regulators leading to 
addiction, and could serve as valuable targets for 
more efficient therapies. In this review, the aim is to 
provide an overview of the emerging role of miRNAs in 
addiction.
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(miR-212,  miR-133b,  miR-132,  miR-181a,  miR-140, 
miR-190,  and  so  on  [4-13])  in  dendritic  spine 
morphogenesis  and  the  development  of  addiction  [3-
5,10,11,14-16].  Table  1  lists  miRNAs  that  have  been 
found to be involved in addiction, and the mechanisms 
that they affect. In this review, the aim is to present the 
recent advances in the field, highlighting the emerging 
role of miRNAs in addiction. These miRNAs have been 
implicated  in  the  mechanisms  of  drug  addiction,  and 
further  studies  may  be  central  for  developing  novel 
therapeutic targets of this major brain disorder.
Figure 1.   Simplified overview of the pathways involved in miRNA regulation of gene expression in addiction. Neurotransmitters activate 
intracellular signaling pathways through binding to their different receptors, leading to activation of transcription factors. Transcriptional activation 
induces transcription of a large program of plasticity-related genes – leading to synaptic adaptation and favoring the formation of the addictive 
phenotype – together with transcription of primer miRNAs. Primer miRNAs are processed by Drosha/DGCR8, and then exported by exportin 5 
as precursor miRNAs to be converted to mature miRNA by Dicer and other nucleases. Upon strand selection, the selected strand of the mature 
miRNA binds with Ago2 and the Risc complex to interact with its specific target. Perfect match with the target mRNA induces deadenylation and 
mRNA cleavage, while imperfect match prevents binding to ribosomes and blocks translation: in both cases expression is silenced. In many cases, 
miRNAs regulate gene expression (including plasticity-related genes) in a dynamic double negative feedback loop, as exemplified here with miR-
181a/miR-124/let-7d, involved in cocaine (adapted from [10,11]): the brain-enriched miR-124 is suppressed by chronic cocaine in the mesolimbic 
dopaminergic pathway (presumably by the induction of REST), which induces expression of genes encoding miR-124 targets (BDNF, integrin β1, 
NAC1, axon guidance molecules such as SEMA6A, and so on), while downregulation of let-7d by cocaine results in induction of the genes encoding 
its targets (μ-opioid receptor, dopamine receptor D3R, semaphorins SEMA6A and SEM4C, PLAU, and so on); these genes (upregulated by cocaine) 
markedly induce miR-181a, causing downregulation of its targets (RGS4, PI4K2B, Per2, and so on), which in turn regulate expression of miR-124a 
and let-7d. Abbreviations: Ago2, argonaute 2; ATF2, cAMP-dependent transcription factor 2; BDNF, brain-derived neurotrophic factor; CREB, cAMP-
responsive element binding protein; DGCR8, DiGeorge syndrome critical region protein 8; Dicer, double-stranded RNA endoribonuclease III; 4E-BP, 
translational repressor protein; eEF1A, elongation factor 1A; eIF-4E, eukaryotic translation initiation factor 4E; MAPK, mitogen-activated protein 
kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3 kinase; PKA, protein kinase A; PLCγ: phospholipase C-γ; Risc, RNA-
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Cocaine use is a common disorder of neuroplasticity that 
triggers cellular and molecular alterations in brain reward 
systems,  mainly  in  the  dorsal  striatum.  Compulsive 
cocaine use and cocaine relapse is due to drug-induced 
neuroadaptations  in  reward-related  learning  and 
memory processes, and these cause hypersensitivity to 
cocaine-associated cues, impulsive decision making and 
abnormal habit-like learned behaviors that are insensitive 
to  adverse  consequences  [3].  Cocaine-induced 
neuroplasticity  changes  in  the  mesolimbic  dopamine 
system mediate psychomotor sensitization and cocaine-
seeking behaviors. Hollander et al. [4] demonstrated that 
cocaine-seeking  behavior  in  rats  is  modulated  by 
miR-212, which decreases the activity of a group of genes 
(CREB,  TORC1,  Raf1  and  SPRED1),  thus  limiting  the 
transition to an uncontrolled intake of cocaine in animals 
exposed  to  the  drug  over  a  long  period  of  time. 
Interestingly,  artificially  increasing  miR-212  expression 
leads  to  decreased  cocaine  intake  under  conditions  of 
extended access, whereas blocking the expression of this 
regulatory  miRNA  increases  cocaine  intake. 
Furthermore, cocaine addiction, commonly viewed as a 
disorder of neuroplasticity, affects expression of MeCP2; 
MeCP2  regulates  cocaine  intake  through  homeostatic 
interactions  with  miR-212  to  control  the  effects  of 
cocaine  on  striatal  brain-derived  neurotrophic  factor 
(BDNF)  levels,  leading  to  synaptic  plasticity  and  thus 
regulating vulnerability to cocaine [15].
Cocaine  also  affects  the  expression  of  a  number  of 
other  miRNAs:  miR-124  and  let-7d  are  suppressed, 
whereas miR-181a is induced after chronic cocaine use 
[10]. Cocaine causes a strong induction of miR-181a in 
different regions of the midbrain. The role of miR-181a in 
lineage modulation-determining ratio of cell types and as 
a  positive  modulator  of  B  cell  differentiation  is  well 
established,  and  miR-181a  has  putative  target  sites  on 
several cocaine-suppressed genes: BDNF, DAT, mGluR5, 
Homer1, Drd3 (dopamine receptor D3R), Per2 and CREB 
[6]. Interestingly Per2 is induced after cocaine exposure, 
but  mPer2  mutant  mice  exhibit  a  hypersensitized 
response to cocaine and show a strong cocaine-induced 
place  preference.  While  chronic  cocaine  decreases 
surface  production  of  mGluR5  and  Homer  1  in  the 
nucleus  accumbens,  and  withdrawal  increases  their 
production  in  the  dorsal  prefrontal  cortex,  miR-181a 
Table 1. MiRNAs involved in addiction
Drug  miRNAs involved  Mechanisms affected  References
Cocaine  miR-212  Decreases activity of CREB and TORC1, and controls expression of gene encoding BDNF via  
    interaction with MeCP2  [4,15]
  miR-181a  Upregulated by cocaine; affects expression of genes encoding BDNF, DAT, CREB, Homer1 and Drd3  [10,11]
  let-7d  Downregulated by cocaine; targets semaphorins, BDNF, neuropilins and mGluR5  [10,11]
  miR-124  Downregulated by cocaine; targets Drd3, DAT and FosB  [10,11]
  miR-324-5p  Induced by Arg2 in Drd2 neurons; regulates cdk5r1, FosB and Mef2d  [5,9]
  miR-369-3p  Induced by Arg2 in Drd2 neurons; regulates cdk5r1, FosB and Mef2d  [5,9]
Nicotine  miR-140  Induced by nicotine; regulates dynamin-1, regulates synaptic endocytosis  [12,16]
  miR-504  Upregulates gene encoding Drd1  [12,16]
Opiates  miR-23b  Induces mOR  [19]
  miR-190  Induced by mOR by upregulation of talin2  [13,19]
  miR-15b, miR-181b  Induced by morphine  [20,21]
    Induced by morphine 




  miR-133b  Specifically expressed in dopaminergic neurons; downregulates expression of gene encoding Pitx3;   [6,21]
    Pitx3 induces production of TH and DAT and regulates maturation of midbrain dopaminergic neurons
  miR-16  Induced by SSRI in serotonergic neurons; reduces expression of gene encoding SERT  [23]
  miR-9  Induced by alcohol; downregulates BK channels   [4]
  miR-212  Induced by alcohol; decreases ZO-1, affects cell permeability  [22]
  miR-27b  Downregulates CYP3A4  [17]
  miR-298  Downregulates CYP3A4  [17,24]
Arg2, arginase, type II; cdk5r1, cyclin-dependent kinase 5, regulatory subunit 1; CREB, cAMP-responsive element binding protein; BDNF, brain-derived neurotrophic 
factor; CYP3A4, cytochrome P450 3A4; DAT, dopamine transporter; Drd1, dopamine receptor D1R; Drd2, dopamine receptor D2R; Drd3, dopamine receptor D3R; FosB, 
FBJ murine osteosarcoma viral oncogene homolog B; MeCP2, methyl CpG binding protein 2; Mef2d, myocyte enhancer factor 2D; mGluR5, metabotropic glutamate 
receptor 5; SSRI, selective serotonin reuptake inhibitor; TH, tyrosine hydroxylase; TORC1, transducer of regulated CREB activity 1; ZO-1, tight junction protein.
Dreyer Genome Medicine 2010, 2:92 
http://genomemedicine.com/content/2/12/92
Page 3 of 7reveals a correlating inverse expression pattern with the 
expression pattern of mGluR5 in these regions [10,11]. 
Chronic cocaine also mediates downregulation of miR-
124a in the mesolimbic dopaminergic pathway, and this 
could  have  a  greatest  impact  on  the  targeted  gene 
expression  (for  example,  DAT,  FosB,  CREB  and  Drd3) 
[10,11].  miR-124a  is  an  exclusively  neuronal  miRNA, 
highly conserved between invertebrates and vertebrates, 
and  accounts  for  25-48%  of  total  adult  brain  miRNA. 
Dysregulation of let-7 miRNA seems to play a crucial role 
in  the  etiology  of  neurological  disorders.  The  CA1 
pyramidal cells of the hippocampus have high levels of 
μ-opioid  receptors  and  cocaine  activation  may 
differentially  modulate  memory  processes,  synaptic 
plasticity  and  the  encoding  of  information.  Chronic 
cocaine use suppresses let-7d [5,9], which has a putative 
binding  site  in  the  μ-opioid  receptor  in  the  CA1, 
suggesting that downregulation of let-7d is crucial in the 
development of drug dependence. miRNAs can indirectly 
regulate  their  own  expression  through  double-negative 
feedback loops. It has been proposed [10,11] that these 
miRNAs (124, let-7d and 181a), together with their target 
transcription regulator genes (CREB, NAC1 and REST1), 
along  with  various  target  plasticity-related  genes 
(encoding  semaphorins,  BDNF  and  neuropilins)  and 
neurotransmitter  receptor  genes  (encoding  dopamine 
receptor D3R, μ-opioid receptor, mGluR5 and AMPA-R) 
might act in such a feedback loop during the development 
of  cocaine-induced  neural  plasticity.  Therefore  these 
miRNAs may play an important role in the development 
of addiction.
Finally, argonaute 2 (Ago2) plays an important role in 
miRNA  generation  and  execution  of  miRNA-mediated 
gene  silencing,  and  is  involved  in  the  regulation  of 
cocaine addiction [5]. Deficiency of Ago2 in dopamine 
receptor D2R (Drd2)-expressing neurons greatly reduces 
the motivation to self-administered cocaine in mice. A 
distinct  group  of  miRNAs  is  specifically  regulated  by 
Ago2  in  the  striatum  [5].  Comparison  of  miRNAs 
affected  by  Ago2  deficiency  with  miRNAs  that  are 
enriched  and/or  upregulated  in  Drd2  neurons  in 
response  to  cocaine  identified  a  set  of  23  Ago2-
dependent,  induced  by  cocaine  and  Drd2-enriched 
(ADICD) miRNAs that are likely to play a role in cocaine 
addiction  [9].  These  ADICD  miRNAs  (for  example, 
miR-431, miR-212, miR-324-5p, miR-369-3p, and so on) 
contribute to cocaine addiction and to the regulation of 
genes  important  for  the  development  of  cocaine 
addiction;  these  genes  include  Cdk5r1  and  the 
transcription factors FosB and Mef2d. The contribution 
of  individual  ADICD  miRNAs  to  various  facets  of 
addictive behavior in mice, and possibly humans, remains 
to be investigated further, but may provide useful paths 
to new therapies.
Nicotine
As  a  drug  of  abuse,  nicotine,  an  agonist  of  nicotinic 
acetylcholine receptors, induces neural plasticity leading 
to addiction. Exposure to nicotine can disrupt this finely 
programmed coordination and alter gene expression of a 
diversity of genes in different brain regions, mainly genes 
encoding  synaptic-vesicle-related  proteins  involved  in 
endocytosis  and  exocytosis  (dynamin-1,  synapsin-1, 
syntaxin-7, and so on), neurotransmitter receptors, ion 
channels  and  transporters  (dopamine  Drd1  receptor, 
γ-amino  butyrate  (GABA)A  receptor  β-subunits, 
serotonin  receptor  5A,  and  sodium  and  potassium 
channels),  and  kinases  and  phosphatases  for  signal 
transduction  [12].  Nicotine  selectively  modulates 
expression of multiple miRNAs and increases expression 
of  miR-140,  coordinated  with  the  nicotine-augmented 
expression of its host gene WWP2. miR-140 targets the 
3’UTR of the gene encoding dynamin-1 by direct-base 
pairing [12,16]. Because dynamin-1 has an essential role 
in  synaptic  endocytosis  in  the  central  nervous  system, 
nicotine-induced  miRNA-mediated  regulation  may 
illustrate  its  importance  in  neural  plasticity,  which 
underlies a molecular mechanism of nicotine addiction. 
Furthermore,  the  dopamine  receptor  gene  DRD1  is 
associated with nicotine dependence, with two alleles (A 
and G) of polymorphism rs686 in the 3’UTR of DRD1 
being  expressed  differentially.  It  has  been  shown  that 
miR-504  (not  miR-296)  upregulates  reporter  luciferase 
activity and increases Drd1 production by targeting the 
DRD1  3’UTR,  whereas  inhibition  of  miR-504,  not 
miR-296, has the opposite effect [16]. The direct binding 
of miR-504 to the DRD1 3’UTR, verified by site-directed 
mutagenesis,  causes  a  significant  expression  difference 
between  the  two  alleles.  This  shows  that  miR-504 
upregulates  DRD1  expression  by  direct  binding  to  the 
3’UTR,  and  this  leads  to  differential  allele-specific 
expression  of  DRD1.  Interestingly,  the  variant  is  also 
associated with alcohol dependence and autism spectrum 
disorder, providing additional genetic evidence of DRD1 
and its importance in neuropsychiatric disorders [12,16]. 
This miRNA-mediated differential modulation of DRD1 
expression may alter the density of the DRD1 receptor in 
the brain. Because of the significant role of the DRD1 
receptor  in  mediating  dopamine  action,  the 
predisposition of DRD1 expression may contribute to the 
molecular mechanisms underlying nicotine dependence. 
Furthermore,  because  miR-504  is  chromosome  X 
associated,  the  modulation  of  DRD1  expression  by 
miR-504 may play a role in the sex influences on nicotine 
dependence [12].
Opiates
Opiates  affect  multiple  structures  that  provide  major 
afferent input to the ventral tegmental area (that is, the 
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sources  of  GABA  input;  the  prefrontal  cortex,  the 
amygdala,  and  the  mediodorsal  thalamus  as  primary 
sources  of  glutamate  input;  and  the  pedunculopontine 
tegmental  nucleus  as  a  source  of  acetylcholine  input. 
These structures are characterized by a high density of 
opiate  receptors  and  dense  reciprocal  connections  and 
are implicated in the mediation of goal-directed behavior 
and  the  rewarding  effects  of  psychostimulants  [17,18]. 
Opiate abuse may destabilize neuronal functions, and in 
HIV-1-infected individuals it may lead to an accelerated 
form  of  HIV-1-associated  dementia.  A  strong 
relationship  seems  to  exist  between  opiate  usage  and 
HIV-1  neuropathogenesis.  Opiates  promote  HIV-1 
propagation in immune cells, while suppressing immune 
functions.  miRNA-based  analysis  identified  a  role  of 
miR-23b in the regulation of the μ-opioid receptor [19]. 
In  turn,  the  μ-opioid  receptor  regulates  miR-190 
in  an  agonist-dependent  manner,  via  yingyang-1 
phosphorylation; fentanyl, but not morphine, decreases 
the  miR-190  level  in  rat  primary  hippocampal  neuron 
cultures.  miR-190  is  conserved  and  located  in  the 
intronic regions of the talin2 gene. Yinyang-1 regulates 
the  activity  of  the  talin2  promoter  and  transcription 
regulation of talin2 could modulate the overall miR-190 
level within the hippocampal neurons [19]. Furthermore, 
in  mouse  hippocampi,  miR-190  expression  is 
differentially  regulated  by  μ-opioid  receptor  agonists 
[13].  In  addition,  differentially  expressed  miRNAs,  for 
example  miR-15b  (which  is  upregulated  by  morphine 
treatment) and miR-181b, have several targets in the pro-
inflammatory pathways and may have a potential role for 
inducing  inflammation  and  oxidative  stress  in  human 
monocyte-derived macrophages, thereby contributing to 
HIV-1 central nervous system reservoir expansion and 
disease progression [20]. In addition to these effects on 
miR-190, morphine decreases miR-133b expression, and 
hence increases the production of its target, Pitx3, which 
is  a  transcription  factor  that  activates  tyrosine 
hydroxylase  and  the  dopamine  transporter  [6].  Taking 
into consideration the implication of the dopaminergic 
system  in  addictive  disorders,  including  addiction  to 
opioid  drugs,  these  results  provide  evidence  that  the 
miR-133b is a possible new target for the design of new 
treatments against addictive disorders.
Antidepressants and alcohol
Neuroplasticity of the midbrain-forebrain dopaminergic 
circuits  regulate  a  diverse  set  of  behaviors,  from  the 
control  of  movement  to  modulation  of  cognition  and 
desire;  this  is  because  these  circuits  relate  to  mood, 
attention,  reward  and  addiction.  Defects  in  these 
pathways, including neurodegeneration, are implicated in 
a variety of psychiatric and neurological diseases, such as 
schizophrenia,  attention-deficit/hyperactivity  disorder 
and drug addiction. Recently, the roles of some miRNAs 
in  mammalian  midbrain  dopaminergic  neurons  have 
been identified, and they have been found to relate to 
addictive behaviors. In particular, miR-133b is specifically 
expressed  in  midbrain  dopaminergic  neurons  and  is 
deficient  in  midbrain  tissue  from  patients  [6,21].  miR-
133b  is  interesting  because  it  regulates  the  maturation 
and function of midbrain dopaminergic neurons within a 
negative-feedback  circuit  that  includes  the  paired-like 
homeodomain  transcription  factor  Pitx3.  miR-133b 
functions  within  such  a  feedback  loop,  as  Pitx3 
specifically induces transcription of miR-133b, and Pitx3 
activity  is  downregulated  by  miR-133b  post-
transcriptionally [21]. Furthermore, deletion of the gene 
encoding Dicer leads to the progressive loss of midbrain 
dopaminergic neurons, suggesting that other miRNAs in 
addition  to  miR-133b  function  in  these  cells  and  are 
involved  in  the  fine  tuning  of  dopaminergic-related 
behaviors such as reward and addiction [21].
Other miRNAs may play a role in specific responses to 
drugs of neural circuits in this brain area, as illustrated in 
alcohol tolerance [4]. Addiction to drugs (and alcohol) is 
characterized  by  compulsive  drug  taking  and  seeking, 
and  the  dorsal  striatum  has  been  implicated  in  such 
maladaptive persistent habits. Recently miR-9 has been 
found to be involved in this process, and to destabilize 
the mRNA of the calcium-activated and voltage-activated 
potassium  channel  BK  [4],  which  is  a  well-established 
alcohol target. This effect is restricted to a specific BK 
splice variant harboring a miR-9 recognition element in 
its 3’UTR. Furthermore, alcohol also increases miR-212 
expression, which decreases ZO-1 protein levels, disrupts 
tight  junctions,  and  increases  cell  permeability  [22], 
providing  a  further  example  of  the  control  of  mRNA 
expression by miRNA in addiction.
In  addition,  addictive  behaviors,  and  particularly 
relapse,  are  much  related  to  mood  disorders  and 
depressive states, which are generally associated with a 
deficit  of  serotonin,  a  neurotransmitter  particularly 
involved  in  eating  and  sexual  behaviors,  anxiety  and 
mood problems, the sleep-wake cycle, and also with pain. 
A recent study showed that the miRNA miR-16 controls 
synthesis of serotonin transporter (SERT), which clears 
away serotonin [23]. miR-16 is expressed at higher levels 
in noradrenergic than in serotonergic cells; its reduction 
in  noradrenergic  neurons  causes  de  novo  SERT 
production. In mice, chronic treatment with the selective 
serotonin reuptake inhibitor fluoxetine (Prozac) increases 
miR-16  levels  in  serotonergic  raphe  nuclei,  and  this 
reduces SERT production and releases the neurotrophic 
factor  S100b,  which  acts  on  noradrenergic  cells  of  the 
locus ceruleus. By decreasing miR-16, S100b turns on the 
expression  of  serotonergic  functions  in  noradrenergic 
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action  of  selective  serotonin  reuptake  inhibitor 
antidepressants in monoaminergic neurons [23].
miRNAs and CYP3A4
CYP3A4  is  a  member  of  the  cytochrome  P450  (CYP) 
mixed-function oxidase system, and is one of the most 
important enzymes involved in the metabolism of drugs 
in the body. CYP3A4 is involved in the oxidation of the 
largest  range  of  substrates  of  all  the  cytochromes  P450, 
and  it  metabolizes  most  of  the  drugs  on  the  market, 
particularly  benzodiazepines  and  also  HIV  antivirals, 
macrolide antibiotics and statins. It is induced by many 
drugs  of  abuse  and,  as  a  methadone-metabolizing 
enzyme,  it  interacts  with  many  drugs  and  substances 
used  in  therapies  (antabuse,  barbiturates,  aldactone, 
cannabinoids, Prozac, and so on). As a result, CYP3A4 is 
the  CYP  present  in  the  largest  quantity.  Although 
transcriptional regulation of CYP3A4 is tightly controlled 
by  some  nuclear  receptors  including  the  vitamin  D 
receptor  (VDR/NR1I1),  post-transcriptional  regulation 
of  CYP3A4  remains  elusive.  CYP3A4  activity  is 
significantly decreased by miR-27b and miR-298, but not 
by miR-122a or miR-328, indicating that gene expression 
may  be  regulated  by  specific  miRNAs  at  the 
transcriptional  level  and  the  post-transcriptional  level 
[17].  The  decrease  in  CYP3A4  protein  production  is 
associated with significantly decreased CYP3A4 mRNA 
levels. Also, interactions and downregulation of miR-27b 
or miR-298 with the vitamin D receptor 3’UTR have been 
observed [24]. These data show the role of miRNAs in the 
complex regulation of CYP3A4, which is a central drug 
metabolizing enzyme.
Future directions
From the studies described here it is clear that specific 
drugs  affect  specific  pathways  and  implicate  specific 
miRNAs as key regulators. Future studies will be required 
to  identify  the  specific  targets  or  genetic  networks 
through  which  miRNAs  selectively  influence  pathways 
underlying  drug  addiction.  Collectively,  these 
observations will reveal a new class of drug-related genes 
and, as such, provide new ways in our understanding of 
addiction.  Thorough  description  of  the  intracellular 
pathways involved and the genes regulated by these drug-
specific  miRNAs  is  strongly  needed  and  must  be 
established.  Further  searches  for  specific  miRNAs 
implicated in different types of drug addiction will then 
enable  stronger  and  more  specific  therapies.  Targeting 
these  miRNAs  may  be  a  challenging  but  valuable 
approach that must be investigated, and it could prove 
useful  for  treating  addiction.  Future  studies  will  also 
establish  whether  some  miRNAs  may  affect  common 
genes or pathways implicated in multidrug addiction.
Conclusions
These  studies  identify  the  correlation  between  miRNA 
regulation and addiction. Clearly a number of miRNAs 
may  respond  specifically  to  different  drugs  and  thus 
regulate different pathways in response to a specific drug 
and  differentially  affect  drug-induced  neuroplasticity. 
The mechanistic reach of miRNAs extends well beyond 
suppression  of  gene  expression  and  encompasses  a 
complex system of post-transcriptional control. miRNAs 
have  the  ability  to  form  autoregulatory  loops  and  can 
attract  a  variety  of  activities  to  their  targets  –  even 
stimulating  translation  [25].  The  complex  outcome  for 
the  mRNAs  targeted  by  miRNAs  suggests  their 
involvement in homeostatic or switch-like events during 
various phases of synaptic plasticity. miRNAs may thus 
serve  as  potent  spatiotemporal  regulators  of  complex 
learning-related synaptic plasticity [26], fine-tuning the 
levels of hundreds of proteins simultaneously and in a 
bidirectional manner, to direct gene-silencing processes 
critical for maintenance of addiction phenotype. There-
fore, therapeutic strategies based on modulation of miRNA 
activity  hold  great  promise  because  of  their  ability  to 
potently  affect  gene  expression  and  gene  regulation. 
Future studies will reveal the roles of miRNA as diag-
nostic biomarkers and as potential targets for therapeutic 
intervention for addiction and related brain disorders.
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